Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Immunomedics Inc (IMMU)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,534,344
  • Shares Outstanding, K 190,428
  • Annual Sales, $ 2,160 K
  • Annual Income, $ -273,840 K
  • 60-Month Beta 2.08
  • Price/Sales 1,584.54
  • Price/Cash Flow N/A
  • Price/Book 10.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.36
  • Number of Estimates 5
  • High Estimate -0.30
  • Low Estimate -0.41
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -157.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.82 +32.92%
on 02/26/19
18.69 -1.71%
on 03/18/19
+4.14 (+29.09%)
since 02/15/19
3-Month
11.55 +59.05%
on 01/18/19
18.73 -1.92%
on 12/19/18
+0.35 (+1.94%)
since 12/18/18
52-Week
11.55 +59.05%
on 01/18/19
27.33 -32.78%
on 07/18/18
+2.75 (+17.61%)
since 03/16/18

Most Recent Stories

More News
Immunomedics Appoints Barbara G. Duncan to Board of Directors

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the appointment of Barbara G. Duncan...

IMMU : 18.65 (+0.48%)
Global Biotech Market Primed for Growth With Renewed Research and Development Efforts

Diseases are commonplace around the world, especially in regions that don't have access to adequate healthcare. They present themselves as various groups such as cancers, diabetes, skin, bacterial, as...

MGNX : 19.13 (+0.10%)
VYGR : 19.33 (-1.68%)
ZLAB : 29.47 (+1.66%)
PRTA : 14.65 (+2.09%)
ABBV : 80.98 (-0.44%)
XBIT : 9.49 (+3.49%)
PBIO : 3.2700 (unch)
IMMU : 18.65 (+0.48%)
Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference

Immunomedics, Inc., (NASDAQ: IMMU) ("Immunomedics" or the "Company"), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the Company will participate...

IMMU : 18.65 (+0.48%)
Research Report Identifies Axalta Coating, The Home Depot, Immunomedics, Kosmos Energy, Casa, and Ormat Technologies with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Axalta Coating Systems Ltd. (NYSE:AXTA),...

CASA : 9.02 (+0.78%)
AXTA : 25.82 (-0.54%)
HD : 182.59 (+0.20%)
IMMU : 18.65 (+0.48%)
KOS : 6.05 (+2.02%)
ORA : 55.61 (+0.43%)
Lawsuit for Investors in NASDAQ: IMMU shares against Immunomedics, Inc. announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in NASDAQ: IMMU shares over alleged securities laws violations by Immunomedics, Inc.

IMMU : 18.65 (+0.48%)
CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

SVXY : 53.39 (+0.13%)
ALKS : 34.60 (+1.70%)
IMMU : 18.65 (+0.48%)
Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announces Senior Leadership Changes

Preparation for Resubmission of BLA for Sacituzumab Govitecan Continuing

IMMU : 18.65 (+0.48%)
CLASS ACTION UPDATE for IMMU, DXC and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have...

W : 166.30 (+0.17%)
IMMU : 18.65 (+0.48%)
DXC : 66.04 (+0.44%)
IMMUNOMEDICS 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Immunomedics, Inc. - IMMU

ClaimsFiler, a FREE shareholder information service, reminds investors that they have only until February 25, 2019 to file lead plaintiff applications in a securities class action lawsuit...

IMMU : 18.65 (+0.48%)
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against DXC Technology, Immunomedics, Natural Health, and Maiden Holdings and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of DXC Technology Company, Immunomedics, Inc., Natural Health Trends Corp., and Maiden...

MHLD : 0.73 (+17.74%)
NHTC : 12.96 (-2.63%)
DXC : 66.04 (+0.44%)
IMMU : 18.65 (+0.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade IMMU with:

Business Summary

Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized...

See More

Key Turning Points

2nd Resistance Point 19.11
1st Resistance Point 18.83
Last Price 18.65
1st Support Level 18.04
2nd Support Level 17.53

See More

52-Week High 27.33
Fibonacci 61.8% 21.30
Fibonacci 50% 19.44
Last Price 18.65
Fibonacci 38.2% 17.58
52-Week Low 11.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar